AVGR - Avinger, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0450
-0.0350 (-3.24%)
As of 2:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0800
Open1.0900
Bid1.0400 x 27000
Ask1.0500 x 1300
Day's Range1.0400 - 1.0900
52 Week Range1.0400 - 14.8000
Volume304,738
Avg. Volume456,242
Market Cap10.699M
Beta (3Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-7.0200
Earnings DateMay 4, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Avinger Announces Full Commercial Launch of Pantheris SV

    REDWOOD CITY, CA / ACCESSWIRE / September 18, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the full commercial launch of the Pantheris SV (small vessel) image-guided atherectomy system in the U.S. All current and prospective Lumivascular accounts are now eligible to order the Pantheris SV device. Avinger launched Pantheris SV at select Avinger sites in late July in order to demonstrate the product's ease of use and efficiency across a variety of user approaches and vascular conditions in a real-world clinical setting, as well as train clinical support and sales personnel in best practices with this new device.

  • ACCESSWIRE

    Avinger to Present at Ladenburg Thalmann Healthcare Conference on September 24

    REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that ...

  • ACCESSWIRE

    Avinger Announces Commercial Launch and First Patients Treated in Hong Kong

    REDWOOD CITY, CA / ACCESSWIRE / September 10, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products in Hong Kong. Avinger has an exclusive distribution agreement with Integmed Ltd. for the sale and marketing of Avinger’s Pantheris image-guided atherectomy and Ocelot image-guided chronic total occlusion (CTO) crossing systems in Hong Kong. Dr. Yiu Che Chan, a highly-experienced vascular surgeon and a clinical associate professor at The University of Hong Kong, performed the first four cases using Lumivascular technology in Hong Kong at Queen Mary Hospital.

  • ACCESSWIRE

    Avinger Supports Peripheral Artery Disease (PAD) Awareness Month with Physician and Patient Programs in September

    REDWOOD CITY, CA / ACCESSWIRE / September 4, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), urges greater awareness for this disease state in support of PAD Awareness Month in September. Avinger plans to support PAD Awareness Month through the distribution of informational articles and content related to PAD throughout September, directed both at physicians and patients. In the United States alone, up to 20 million individuals are estimated to suffer from PAD, yet the condition is often under-recognized, under-diagnosed, and under-treated in part because many PAD patients are asymptomatic or dismiss their symptoms as normal age-related complications.

  • ACCESSWIRE

    Avinger Announces 50th Patient Treated in Pantheris SV Initial Launch

    REDWOOD CITY, CA / ACCESSWIRE / August 29, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported significant progress in the initial U.S. launch of the Pantheris SV (small vessel) image-guided atherectomy system. To date, physicians in 10 clinical centers have used Pantheris SV to successfully treat 50 patients in the U.S. Based on positive clinical reports and physician feedback from these initial sites, the Company is ramping production of Pantheris SV in preparation for full commercial launch, which is anticipated to begin in September. Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for the treatment of PAD and increases the number of addressable procedures for the Company’s Lumivascular technology by allowing physicians to target more distal regions of the vasculature in smaller diameter vessels.

  • GlobeNewswire

    Avinger Closes $4.5 Million Equity Offering

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Prospectus Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at prospectus@aegiscap.com, or by telephone at (212) 813-1010.This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

  • GlobeNewswire

    Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures.

  • GlobeNewswire

    Avinger Announces Proposed Underwritten Public Offering of Common Stock

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures.

  • ACCESSWIRE

    Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference

    REDWOOD, CA / ACCESSWIRE / August 19, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the Company’s Lumivascular technology at the annual AMP (Amputation Prevention Symposium) conference occurring last week.

  • Thomson Reuters StreetEvents

    Edited Transcript of AVGR earnings conference call or presentation 31-Jul-19 8:30pm GMT

    Q2 2019 Avinger Inc Earnings Call

  • GlobeNewswire

    Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019

    Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a.

  • GlobeNewswire

    Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States

    Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with the Pantheris SV (Small Vessel) image-guided atherectomy system. Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for the treatment of PAD and increases the number of addressable procedures for the Company’s Lumivascular technology by allowing physicians to target more distal regions of the vasculature in small diameter vessels.

  • GlobeNewswire

    Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019

    REDWOOD CITY, Calif., July 26, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided,.

  • ACCESSWIRE

    Avinger Announces Presentations by Key Opinion Leaders at CVC 2019

    REDWOOD CITY, CA / ACCESSWIRE / July 16, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced five podium presentations and a live case featuring the Company’s Lumivascular technology at the annual CVC conference occurring last week.

  • ACCESSWIRE

    Avinger Enrolls First 50 Patients in INSIGHT Clinical Trial

    REDWOOD CITY, CA / ACCESSWIRE / July 10, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the 50th patient enrolled in its INSIGHT clinical trial. The INSIGHT trial is a prospective, global, single arm, multi-center study to evaluate the safety and effectiveness of the Pantheris® Lumivascular atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. Dr. Jaafer Golzar, Avinger’s Chief Medical Officer and a highly experienced interventionalist, noted, “We are pleased to have the first 50 cases completed as part of our INSIGHT IDE study.

  • ACCESSWIRE

    Avinger Announces Commercial Launch of Ocelot in Australia

    REDWOOD, CA / ACCESSWIRE / July 8, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Ocelot image-guided chronic total occlusion (CTO) crossing system in Australia. As part of the Company’s exclusive distribution agreement with Diverse Devices Pty Ltd. for Avinger’s proprietary Lumivascular products in Australia, Ocelot completed the registration process with the Therapeutic Goods Administration (TGA) and is included on the Australian Register of Therapeutic Goods, which permits distribution in Australia.

  • GlobeNewswire

    Avinger to Effect One-for-Ten Reverse Stock Split

    Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Friday, June 21, 2019. As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock.

  • ACCESSWIRE

    Avinger Announces Distribution Agreement for Hong Kong

    REDWOOD CITY, CA / ACCESSWIRE / June 4, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has entered into an exclusive distribution agreement with Integmed Ltd. for the sales and marketing of Avinger's Lumivascular products in Hong Kong. Initial product shipments are anticipated during the current quarter and first patient treatments in Hong Kong are expected to commence in the third quarter of 2019. Integmed is a leading distributor of medical devices in Hong Kong for the treatment of cardiovascular disease, including a portfolio of complementary products for the endovascular treatment of arterial disease.

  • ACCESSWIRE

    Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference

    REDWOOD CITY, CA / ACCESSWIRE / May 30, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...

  • Is Avinger (AVGR) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Avinger (AVGR) Stock Outpacing Its Medical Peers This Year?

    Is (AVGR) Outperforming Other Medical Stocks This Year?

  • ACCESSWIRE

    Avinger Announces Successful Treatment of 1,000th Patient with Next-Generation Pantheris Device

    REDWOOD CITY, CA / ACCESSWIRE / May 16, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that physicians in 78 clinical sites have successfully treated more than 1,000 patients with the next-generation Pantheris image-guided atherectomy system. The next-generation Pantheris was launched on a limited basis in the U.S. following receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) in late May 2018 and features a number of improvements intended to augment the performance and reliability of the product. Importantly, clinical results have remained consistently positive in a variety of lesion types since market launch.

  • Thomson Reuters StreetEvents

    Edited Transcript of AVGR earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Avinger Inc Earnings Call

  • Associated Press

    Avinger: 1Q Earnings Snapshot

    The Redwood City, California-based company said it had a loss of 14 cents per share. The medical device maker posted revenue of $1.8 million in the period. In the final minutes of trading on Wednesday, ...

  • GlobeNewswire

    Avinger Provides First Quarter 2019 Shareholder Update

    REDWOOD CITY, Calif., May 08, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided,.

  • ACCESSWIRE

    Avinger, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Avinger, Inc. (NASDAQ: AVGR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. ...